SEPN
Septerna, Inc.
NASDAQ · USHealthcareBiotechnology
$32.21-3.56%
Price as of Jul 20, 2026
SEPN growth
Septerna, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +7295.6%
- EBITDA
- +38.9%
- EBIT
- +39.0%
- EPS
- +59.7%
- Free cash flow
- +241.0%
- Operating cash flow
- +245.6%
Forward estimates
- Revenue
- -45.3%
- EBITDA
- +74.7%
- EPS
- +5.5%
Three-year CAGR
- Revenue
- +1644.5%
- EBITDA
- +33.3%
- EBIT
- +0.0%
- Net income
- +31.9%
- EPS
- +43.0%
- Free cash flow
- +257.6%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.